A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer

D. L. Ahmann, D. J. Schaid, J. N. Ingle, H. F. Bisel, A. J. Schutt, J. C. Buckner, H. J. Long, J. Rubin

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Ninety-four patients were entered in a clinical trial assessing the clinical activity of cyclophosphamide, doxorubicin, and prednisone (CAP) versus a combination of cyclophosphamide, 5-Flurouracil, and prednisone (CFP) in patients with advanced breast cancer. Objective response rates were comparable, 49% for CFP and 46% for CAP. There was no statistical difference between the duration of response of the two regimens or in time to progression. Most importantly, survival differences were not apparent. Both regimens were clinically tolerable and toxicities, for the most part, were comparable. Thus, no therapeutic advantage existed for either of these polychemotherapy regimens in patients with advanced breast cancer.

Original languageEnglish (US)
Pages (from-to)179-183
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume14
Issue number3
DOIs
StatePublished - Jan 1 1991

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this